Intervention

cabazitaxel

ClinicalTrials.gov intervention label

Clinical trials10

Recruiting0

Common conditions17

Lead sponsors shown9

Clinical trials

10 shown

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in FinlandNCT05701007 · 2023-02-13

Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a DocetaxelNCT02961257 · 2017-05-05

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)NCT02903160 · 2017-01-13

Cabazitaxel in mCRPC Patients With AR-V7 Positive CTCsNCT02621190 · 2016-02-01

Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate CancerNCT02254785 · 2014-10-01

Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial MetastasesNCT01934894 · 2014-05-01

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate CancerNCT01578655 · 2012-08-01

Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With DocetaxelNCT01469338 · 2012-07-01

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)NCT01083615 · 2010-03-01

The JET Study: a Phase I Trial of Cabazitaxel, Radiotherapy and Long-term Androgen DeprivationNCT01981668

Common conditions

Prostate Cancer2 Prostatic Neoplasms2 Castrate-Resistant Prostate Cancer1 Diarrhea1 Hormone Refractory Prostate Cancer1 Hormone-resistant Prostate Cancer1 Metastatic Breast Cancer With Intracranial Metastases1 Metastatic Castration Resistant Prostate Cancer (mCRPC)1 Metastatic Castration Sensitive Prostate Cancer (mCSPC)1 Metastatic Castration-Resistant Prostatic Cancer1 Prostate Cancer Metastatic1 Recurrent Prostate Cancer1 Stage I Prostate Cancer1 Stage IIA Prostate Cancer1 Stage IIB Prostate Cancer1 Stage III Prostate Cancer1 Stage IV Prostate Cancer1

Leading sponsors

Achieve Life Sciences2 Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie1 British Columbia Cancer Agency1 Erasmus Medical Center1 Icahn School of Medicine at Mount Sinai1 Nova Scotia Cancer Centre1 Pfizer1 SCRI Development Innovations, LLC1 University of Southern California1

Trial status mix

COMPLETED4

TERMINATED3

WITHDRAWN2

UNKNOWN1

Phase mix

PHASE25

PHASE33

PHASE11

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.